[
  {
    "ts": null,
    "headline": "Where Will AbbVie Be in 5 Years?",
    "summary": "The company is down slightly this year, but that may be a buying opportunity.",
    "url": "https://finnhub.io/api/news?id=3f96aebaaf64cfcebae46852f1d6e8e858df141c0d20affe99225b30d0a5064d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772138100,
      "headline": "Where Will AbbVie Be in 5 Years?",
      "id": 139239818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The company is down slightly this year, but that may be a buying opportunity.",
      "url": "https://finnhub.io/api/news?id=3f96aebaaf64cfcebae46852f1d6e8e858df141c0d20affe99225b30d0a5064d"
    }
  },
  {
    "ts": null,
    "headline": "IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks",
    "summary": "Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.",
    "url": "https://finnhub.io/api/news?id=bf0f21fd9f2b21a88934ab2a5c16b956a970999219f676366969b383014b9e9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772120400,
      "headline": "IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks",
      "id": 139237059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.",
      "url": "https://finnhub.io/api/news?id=bf0f21fd9f2b21a88934ab2a5c16b956a970999219f676366969b383014b9e9f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s CLL Breakthrough And US$380m Build Out Test Valuation",
    "summary": "AbbVie received FDA approval for a first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for previously untreated chronic lymphocytic leukemia. The company announced a $380 million investment in advanced U.S. manufacturing facilities in North Chicago to support neuroscience and obesity treatments. These developments affect AbbVie’s oncology portfolio and its capacity to produce emerging therapies in key focus areas. For investors watching NYSE:ABBV, the news...",
    "url": "https://finnhub.io/api/news?id=d2cb640712611f71c846aadf5f9cefb1a092af3f83c7db06c831aed182379bc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772093711,
      "headline": "AbbVie’s CLL Breakthrough And US$380m Build Out Test Valuation",
      "id": 139230405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie received FDA approval for a first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for previously untreated chronic lymphocytic leukemia. The company announced a $380 million investment in advanced U.S. manufacturing facilities in North Chicago to support neuroscience and obesity treatments. These developments affect AbbVie’s oncology portfolio and its capacity to produce emerging therapies in key focus areas. For investors watching NYSE:ABBV, the news...",
      "url": "https://finnhub.io/api/news?id=d2cb640712611f71c846aadf5f9cefb1a092af3f83c7db06c831aed182379bc9"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie",
    "summary": "Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie",
    "url": "https://finnhub.io/api/news?id=09a87a4bea1335869f8b9bc61326a1312fc18461b27f445fd70bb784cf5e9447",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772091011,
      "headline": "Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie",
      "id": 139231313,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=09a87a4bea1335869f8b9bc61326a1312fc18461b27f445fd70bb784cf5e9447"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital analyst Trung Huynh initiated coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $260 price target. The analyst noted that the shares have lagged due to concerns that AbbVie’s “beat-and-raise” story […]",
    "url": "https://finnhub.io/api/news?id=7d0e42d07cb819dae61b1fbf4172a5716e1a173743936ba515e152b35eb14543",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772072687,
      "headline": "RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears",
      "id": 139227884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital analyst Trung Huynh initiated coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $260 price target. The analyst noted that the shares have lagged due to concerns that AbbVie’s “beat-and-raise” story […]",
      "url": "https://finnhub.io/api/news?id=7d0e42d07cb819dae61b1fbf4172a5716e1a173743936ba515e152b35eb14543"
    }
  }
]